



## STEP THERAPY POLICY

- POLICY:** Attention Deficit Hyperactivity Disorder Stimulant Medications Step Therapy Policy
- Adderall XR<sup>®</sup> (mixed amphetamine salts [dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate, amphetamine aspartate] extended-release capsules – Shire, generic)
  - Adhansia XR<sup>®</sup> (methylphenidate extended-release capsule – Purdue)
  - Adzenys ER<sup>™</sup> (amphetamine extended-release oral suspension – Neos Therapeutics)
  - Adzenys XR-ODT<sup>™</sup> (amphetamine extended-release orally disintegrating tablets – Neos Therapeutics)
  - Aptensio XR<sup>®</sup> (methylphenidate extended-release capsules – Rhodes, generic)
  - Azstarys<sup>™</sup> (serdexmethylphenidate and dexmethylphenidate capsules – Corium)
  - Concerta<sup>®</sup> (methylphenidate extended-release tablets – McNeil, generic)
  - Cotempla XR-ODT<sup>™</sup> (methylphenidate extended-release orally disintegrating tablets – Neos Therapeutics)
  - Daytrana<sup>®</sup> (methylphenidate transdermal system – Noven, generic)
  - Dexedrine<sup>®</sup> Spansules<sup>®</sup> (dextroamphetamine sustained-release capsules – Amedra, generic)
  - Dyanavel<sup>®</sup> XR (amphetamine extended-release tablets and oral suspension – Tris)
  - Focalin<sup>®</sup> XR (dexmethylphenidate extended-release capsules – Novartis, generic)
  - Jornay PM<sup>®</sup> (methylphenidate hydrochloride extended-release capsules – Ironshore)
  - Metadate<sup>®</sup> CD (methylphenidate extended-release capsules – UCB, generic)
  - Metadate<sup>®</sup> ER (methylphenidate sustained-release tablets – UCB, generic only)
  - methylphenidate extended-release capsules (generic to discontinued Methylin<sup>™</sup> ER)
  - Mydayis<sup>®</sup> (mixed salts of a single-entity amphetamine product extended-release capsules – Shire, generic)
  - QuilliChew ER<sup>®</sup> (methylphenidate extended-release chewable tablets – Pfizer)
  - Quillivant<sup>®</sup> XR (methylphenidate extended-release oral suspension – NextWave)
  - Relexxii<sup>®</sup> (methylphenidate extended-release tablets – Vertical, authorized generic)
  - Ritalin<sup>®</sup> LA (methylphenidate extended-release capsules – Novartis, generic)

- Ritalin-SR<sup>®</sup> (methylphenidate sustained-release tablets – Novartis, generic)
- Vyvanse<sup>®</sup> (lisdexamfetamine dimesylate capsules and chewable tablets – Shire, generic)
- Xelstrym<sup>™</sup> (dextroamphetamine transdermal system – Noven)

**REVIEW DATE:** 04/05/2023; selected revision 09/20/2023 and 11/01/2023

**INSTRUCTIONS FOR USE**

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

**CIGNA NATIONAL FORMULARY COVERAGE:**

**OVERVIEW**

All of the long-acting stimulants are indicated for the treatment of **attention-deficit hyperactivity disorder (ADHD)**.<sup>1-24</sup> Refer to Table 1 for a summary of indications.

- Some products are also indicated for the treatment of **narcolepsy**.
- Vyvanse is the only stimulant medication that is also indicated for the treatment of **binge eating disorder**.<sup>11</sup>

All of these products have abuse potential and are Schedule II controlled substances.<sup>1-24</sup>

**Table 1. FDA-Approved Indications for Long-Acting Stimulants.**<sup>1-24</sup>

<b>Product</b>	<b>FDA-Approved Indication(s)</b>
Adderall XR <sup>®</sup> (generic)	• ADHD in children 6 to 12 years of age, adolescents 13 to 17 years of age, and adults
Adhansia XR <sup>®</sup>	• ADHD in patients ≥ 6 years of age
Adzenys ER <sup>™</sup>	• ADHD in patients ≥ 6 years of age
Adzenys XR-ODT <sup>™</sup>	• ADHD in patients ≥ 6 years of age
Aptensio XR <sup>®</sup> (generic)	• ADHD in patients ≥ 6 years of age
Azstarys <sup>™</sup>	• ADHD in patients ≥ 6 years of age
Concerta <sup>®</sup> (generic)	• ADHD in children ≥ 6 years of age, adolescents 13 to 17 years of age, and adults ≤ 65 years of age
Cotempla XR-ODT <sup>™</sup>	• ADHD in patients 6 to 17 years of age
Daytrana <sup>®</sup>	• ADHD in children 6 to 12 years of age, and adolescents 13 to 17 years of age

<b>Product</b>	<b>FDA-Approved Indication(s)</b>
Dexedrine® Spansule® (generic)	<ul style="list-style-type: none"> <li>ADHD in children ≥ 6 years of age and adolescents up to 16 years of age</li> <li>Narcolepsy</li> </ul>
Dyanavel® XR	<ul style="list-style-type: none"> <li>ADHD in children ≥ 6 years of age and adults</li> </ul>
Focalin® XR (generic)	<ul style="list-style-type: none"> <li>ADHD in patients ≥ 6 years of age</li> </ul>
Jornay PM®	<ul style="list-style-type: none"> <li>ADHD in patients ≥ 6 years of age</li> </ul>
Metadate® CD (generic)	<ul style="list-style-type: none"> <li>ADHD in children 6 to 15 years of age</li> </ul>
Metadate® ER (generic, brand product considered generic per FDB)	<ul style="list-style-type: none"> <li>ADHD in children ≥ 6 years of age and adults</li> <li>Narcolepsy</li> </ul>
Methylin™ ER (generic only, brand discontinued)	<ul style="list-style-type: none"> <li>ADHD in children ≥ 6 years of age and adults</li> <li>Narcolepsy</li> </ul>
Mydayis® (generic)	<ul style="list-style-type: none"> <li>ADHD in patients ≥ 13 years of age and adults</li> </ul>
QuilliChew E®	<ul style="list-style-type: none"> <li>ADHD in children ≥ 6 years of age and adults</li> </ul>
Quillivant® XR	<ul style="list-style-type: none"> <li>ADHD in patients ≥ 6 years of age</li> </ul>
Relexxii®	<ul style="list-style-type: none"> <li>ADHD in children and adolescents ≥ 6 years of age and adults up to 65 years of age</li> </ul>
Ritalin® LA (generic)	<ul style="list-style-type: none"> <li>ADHD in children 6 to 12 years of age</li> </ul>
Ritalin-SR® (generic)	<ul style="list-style-type: none"> <li>ADHD in children ≥ 6 years of age and adults</li> <li>Narcolepsy</li> </ul>
Vyvanse® (generic)	<ul style="list-style-type: none"> <li>ADHD in children 6 to 12 years of age, adolescents 13 to 17 years of age, and adults</li> <li>Binge eating disorder in adults</li> </ul>
Xelstry™	<ul style="list-style-type: none"> <li>ADHD in children ≥ 6 years of age and adults</li> </ul>

ADHD – Attention-deficit hyperactivity disorder.

## **GUIDELINES**

The American Academy of Pediatrics (AAP) clinical practice guideline for the diagnosis, evaluation, and treatment of ADHD in children and adolescents was updated in 2019 and incorporates many of the findings from the Multimodal Treatment Study of Children With ADHD (MTA).<sup>25</sup> The AAP recommendations for treatment of children and youth with ADHD vary depending on the patient’s age. For preschool-aged children (4 to 5 years of age), parent- and/or teacher-administered behavior therapy should be prescribed as first-line treatment; methylphenidate may be prescribed if behavior interventions do not provide significant improvement and disturbance of function continues. For elementary school-aged children (6 to 11 years of age), an FDA-approved medication for ADHD (and/or behavior therapy, but preferably both) should be prescribed. Evidence is particularly strong for stimulant medications, and sufficient but less strong for atomoxetine, guanfacine extended-release (ER) tablets, and clonidine ER tablets (in that order). For adolescents (12 to 18 years of age), an FDA-approved medication for ADHD (and/or behavior therapy, but preferably both) should be prescribed with the assent of the adolescent. The dose of medication should be titrated to achieve maximum benefit with minimum adverse events (AEs). The findings from the MTA study suggested that more than 70% of children and youth with ADHD respond to one of the stimulant medications at an optimal dose when a systematic trial is used. Titration to maximum doses that control symptoms without AEs is recommended instead of titration strictly on a mg-per-kg basis.

Methylphenidate and amphetamine formulations have similar effects and AEs, and remain the first choice of medication treatment.<sup>25</sup> Some patients will respond better

to or display more AEs with one compound vs. another; however, these effects cannot be predetermined. Therefore, if a trial with one group is unsuccessful (poor efficacy or AEs), a trial on a medication from the other group should be undertaken. At least half of the patients whose symptoms fail to respond to one stimulant medication may have a positive response to the alternative medication.

The AAP clinical practice guideline on the identification and management of eating disorders in children and adolescents (2021) notes that research on the treatment of binge eating disorder lags behind that for other eating disorders and has been focused primarily on adults.<sup>26</sup> Vyvanse was approved by the FDA in 2015 for the treatment of moderate to severe binge-eating disorder in adults. Vyvanse has demonstrated efficacy in reducing the frequency of binge-eating episodes. As with the use of other central nervous system stimulants, there is a potential for abuse and dependence as well as serious cardiovascular reactions. Topiramate has been shown to reduce binge eating and help with weight loss; however, the rates of adverse effects are relatively high. Selective serotonin reuptake inhibitors have rarely differed from placebo in their effect on binge-eating disorder and have not shown better outcome than behavioral therapy alone.

### **DOSING AND DOSAGE FORMS**

The choice of formulation depends on factors such as the efficacy of each agent for a given child/adolescent, the preferred length of coverage time, whether a child can swallow tablets or capsules, and expense.<sup>25</sup> The extended-release (ER) formulations may be preferred over immediate-release (IR) formulations because they provide benefits of consistent and sustained coverage with fewer administrations per day. Long-acting formulations usually preclude the need for school-based administration of ADHD medications. Better coverage with fewer administrations leads to greater convenience for the family and, therefore, might also lead to better adherence to the medication management plan. Some patients, particularly adolescents, might require more than 12 hours of coverage to ensure adequate focus and concentration during evening study time and driving; in these cases, a short-acting (IR) preparation might be used in addition to a long-acting (ER) preparation.

Many of the generic ER stimulant medications for the treatment of ADHD are available as capsules: generic amphetamine/dextroamphetamine ER capsules (generic to Adderall XR), generic dexamethylphenidate ER capsules (generic to Focalin XR), and generic methylphenidate ER capsules (generic to Metadate CD, Ritalin LA, Adhansia XR, Aptensio XR). According to the prescribing information, the capsules may be taken whole, or opened and the entire contents sprinkled on applesauce.<sup>1,5,6,9,13,21</sup> Patients should take the applesauce with sprinkled beads in its entirety without chewing.

### **POLICY STATEMENT**

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

**Attention Deficit Hyperactivity Disorder Stimulant Medications product(s) is(are) covered as medically necessary when the following step therapy criteria is(are) met. Any other exception is considered not medically necessary.**

**Step 1:** Generic amphetamine/dextroamphetamine extended-release capsules (generic to Adderall XR), generic dexamethylphenidate extended-release capsules (generic to Focalin XR), generic dextroamphetamine extended-release capsules (generic to Dexedrine Spansules), generic lisdexamfetamine capsules, generic methylphenidate extended-release capsules (generic to Metadate CD and Ritalin LA), Metadate ER (generic according to First Data Bank [FDB]), generic methylphenidate sustained-release tablets (generic to Ritalin SR), generic methylphenidate extended-release tablets (generic to Concerta), generic mixed salts of a single-entity amphetamine product extended-release capsules (generic to Mydayis)

**Step 2:** Adderall XR, Adhansia XR, Adzenys ER, Adzenys XR-ODT, Aptensio XR (brand and generic), Azstarys, Concerta, Cotempla XR-ODT, Daytrana (brand and generic methylphenidate transdermal system), Dexedrine Spansules, Dyanavel XR (tablets and oral solution), Focalin XR, Jornay PM, Metadate CD, Mydayis, QuilliChew ER, Quillivant XR, Relexxii (brand and authorized generic), Ritalin LA, Ritalin SR, Vyvanse capsules, Vyvanse chewable tablets (brand and generic), Xelstrym

## **CRITERIA**

**1.** If the patient has tried one Step 1 Product, approve a Step 2 Product.

## **REFERENCES**

1. Adderall XR<sup>®</sup> extended-release capsules [prescribing information]. Lexington, MA: Takeda; February 2022.
2. Concerta<sup>®</sup> extended-release tablets [prescribing information]. Titusville, NJ: Janssen; June 2021.
3. Daytrana<sup>®</sup> transdermal system [prescribing information]. Miami, FL: Noven; June 2021.
4. Dexedrine<sup>®</sup> Spansule<sup>®</sup> sustained-release capsule [prescribing information]. Bridgewater, NJ: Amneal; January 2022.
5. Focalin XR<sup>®</sup> extended-release capsules [prescribing information]. East Hanover, NJ: Novartis; June 2021.
6. Metadate CD<sup>®</sup> extended-release capsules [prescribing information]. Philadelphia, PA: Lannett; April 2022.
7. Metadate<sup>®</sup> ER extended-release tablet [prescribing information]. Philadelphia, PA: Lannett; June 2021.
8. Methylin<sup>™</sup> tablets and Methylin<sup>™</sup> ER extended-release tablets [prescribing information]. Hazelwood, MO: Mallinckrodt; June 2021.
9. Ritalin LA<sup>®</sup> extended-release capsules [prescribing information]. East Hanover, NJ: Novartis; June 2021.
10. Ritalin<sup>®</sup> tablets and Ritalin SR<sup>®</sup> sustained-release tablets [prescribing information]. East Hanover, NJ: Novartis; November 2019.
11. Vyvanse<sup>®</sup> capsules [prescribing information]. Lexington, MA: Takeda; January 2022.
12. Quillivant<sup>®</sup> XR extended-release oral suspension [prescribing information]. Monmouth Junction, NJ: NextWave; June 2021.

13. Aptensio XR® extended-release capsules [prescribing information]. Coventry, RI: Rhodes; June 2021.
14. QuilliChew ER® extended-release chewable tablets [prescribing information]. Monmouth Junction, NJ: NextWave; June 2021.
15. Dyanavel® XR extended-release tablets and oral suspension [prescribing information]. Monmouth Junction, NJ: Tris; June 2022.
16. Adzenys XR-ODT™ extended-release orally disintegrating tablets [prescribing information]. Grand Prairie, TX: Neos; January 2022.
17. Mydayis® extended-release capsules [prescribing information]. Lexington, MA: Takeda; January 2022.
18. Cotempla XR-ODT™ orally disintegrating tablets [prescribing information]. Grand Prairie, TX: Neos; June 2021.
19. Adzenys ER™ extended-release oral solution [prescribing information]. Grand Prairie, TX: Neos; January 2022.
20. Jornay PM® extended-release capsules [prescribing information]. Cherry Hill, NJ: Ironshore; June 2021.
21. Adhansia XR® extended-release capsules [prescribing information]. Stamford, CT: Adlon; June 2021.
22. Relexxii® extended-release tablets [prescribing information]. Alpharetta, GA: Vertical; June 2022.
23. Azstarys™ capsules [prescribing information]. Grand Rapids, MI: Corium; March 2021.
24. Xelstrym™ transdermal system [prescribing information]. Miami, FL: Noven; March 2022.
25. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. *Pediatrics*. 2019;144(4):e20192528.
26. Hornberger LL, Lane MA; AAP the Committee on Adolescence. Identification and management of eating disorders in children and adolescents. *Pediatrics*. 2021;147(1):e2020040279.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	05/25/2022
Selected Revision	<b>Methylphenidate transdermal system (generic to Daytrana):</b> Addition of the generic to Step 2 and to exception criteria for a patient who cannot swallow or has difficulty swallowing oral dosage forms.	07/20/2022
Selected Revision	<b>Xelstrym:</b> Addition to Step 2 Products. <b>Criterion removal:</b> Removal of the exception criterion for a patient who cannot swallow or has difficulty swallowing oral dosage forms due to numerous options available in Step 1 that can be opened and sprinkled on applesauce.	11/16/2022
Early Annual Revision	<b>Relexxii:</b> Removed reference to “branded generic.” Relexxii is now FDA-approved under a New Drug Application (NDA) and has an authorized generic. <b>Methylphenidate 72 mg extended-release tablets (Trigen):</b> Removed separate listing; this is the authorized generic to Relexxii.	04/05/2023
Selected Revision	<b>Generic lisdexamfetamine capsules:</b> Generic lisdexamfetamine capsules were added to Step 1. <b>Generic lisdexamfetamine chewable tablets:</b> Generic lisdexamfetamine chewable tablets were added to Step 2. <b>Binge eating disorder:</b> The criterion approving Vyvanse for the treatment of binge eating disorder was removed since generic lisdexamfetamine capsules are now available as a Step 1 product.	09/20/2023
Selected Revision	<b>Generic mixed salts of a single-entity amphetamine product extended-release capsules (generic to Mydayis):</b> Added to Step 1.	11/01/2023

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna